Establihment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1)

Kimura, Yoshinao; Kobari, Masao; Yusa, T; Sunamura, Makoto; Kimura, Mitsuhiro; Shimamura, Hiromune; Matsuno, Seiki

doi:10.1007/bf02787375

Cited by 18 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collectively, these data show that whereas some human pancreatic cancer cell lines display certain skeletal muscle atrophy‐inducing properties, their effects are generally small and inconsistent. Moreover, cachexia‐related clinical data of the donor patients of these cell lines are not available, 27 , 28 , 29 questioning their application for modelling pancreatic cancer‐induced cachexia.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Human pancreatic tumour organoid‐derived factors enhance myogenic differentiation

Vaes

Dijk

Farshadi

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Most patients with pancreatic cancer develop cachexia, which is characterized by progressive muscle loss. The mechanisms underlying muscle loss in cancer cachexia remain elusive. Pancreatic tumour organoids are 3D cell culture models that retain key characteristics of the parent tumour. We aimed to investigate the effect of pancreatic tumour organoid-derived factors on processes that determine skeletal muscle mass, including the regulation of muscle protein turnover and myogenesis. Methods Conditioned medium (CM) was collected from human pancreatic cancer cell lines (PK-45H, PANC-1, PK-1, and KLM-1), pancreatic tumour organoid cultures from a severely cachectic (PANCO-9a) and a non-cachectic patient (PANCO-12a), and a normal pancreas organoid culture. Differentiating C2C12 myoblasts and mature C2C12 myotubes were exposed to CM for 24 h or maintained in control medium. In myotubes, NF-kB activation was monitored using a NF-κB luciferase reporter construct, and mRNA expression of E3-ubiquitin ligases and REDD1 was analysed by RT-qPCR. C2C12 myoblast proliferation and differentiation were monitored by live cell imaging and myogenic markers and myosin heavy chain (MyHC) isoforms were assessed by RT-qPCR. Results Whereas CM from PK-1 and KLM-1 cells significantly induced NF-κB activation in C2C12 myotubes (PK-1: 3.1fold, P < 0.001; KLM-1: 2.1-fold, P = 0.01), Atrogin-1/MAFbx and MuRF1 mRNA were only minimally and inconsistently upregulated by the CM of pancreatic cancer cell lines. Similarly, E3-ubiquitin ligases and REDD1 mRNA expression in myotubes were not altered by exposure to pancreatic tumour organoid CM. Compared with the control condition, CM from both PANCO-9a and PANCO-12a tumour organoids increased proliferation of myoblasts, which was accompanied by significant downregulation of the satellite cell marker paired-box 7 (PAX7) (PANCO-9a: À2.1-fold, P < 0.001; PANCO-12a: À2.0-fold, P < 0.001) and myogenic factor 5 (MYF5) (PANCO-9a: À2.1-fold, P < 0.001; PANCO-12a: À1.8-fold, P < 0.001) after 48 h of differentiation. Live cell imaging revealed accelerated alignment and fusion of myoblasts exposed to CM from PANCO-9a and PANCO-12a, which was in line with significantly increased Myomaker mRNA expression levels (PANCO-9a: 2.4-fold, P = 0.001; PANCO-12a: 2.2-fold, P = 0.004). These morphological and transcriptional alterations were accompanied by increased expression of muscle differentiation markers such as MyHC-IIB (PANCO-9a: 2.5-fold, P = 0.04; PANCO-12a: 3.1-fold, P = 0.006). Although the impact of organoid CM on myogenesis was not associated with the cachexia phenotype of the donor patients, it was specific for tumour organoids, as CM of control pancreas organoids did not modulate myogenic fusion. Conclusions These data show that pancreatic tumour organoid-derived factors alter the kinetics of myogenesis, which may eventually contribute to impaired muscle mass maintenance in cancer cachexia.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Human pancreatic cancer cell lines PK‐45H, PANC‐1, 27 PK‐1, 28 and KLM‐1 29 (obtained from RIKEN BioResource Center) were cultured in high glucose (4.5 g/L) Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% ( v / v ) foetal bovine serum (FBS) (Greiner Bio‐one, cat. no.…”

Section: Methodsmentioning

confidence: 99%